What is the treatment for Cannabinoid Hyperemesis Syndrome (CHS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The primary treatment for Cannabinoid Hyperemesis Syndrome (CHS) is complete cessation of cannabis use, which is the only definitive way to resolve symptoms long-term. This is based on the most recent and highest quality study available, which emphasizes the importance of cannabis cessation in managing CHS 1. During acute episodes, supportive care includes intravenous fluids for dehydration, antiemetics such as ondansetron, promethazine, or metoclopramide, and hot showers or baths which many patients report provide temporary relief.

Key Treatment Strategies

  • Complete cessation of cannabis use for at least 6 months or equal to the total duration of 3 typical vomiting cycles in the patient 1
  • Supportive care with intravenous fluids, antiemetics, and hot showers or baths
  • Topical capsaicin cream (0.1%) applied to the abdomen to reduce nausea and vomiting through TRPV1 receptor activation 1
  • Benzodiazepines like lorazepam may help with associated anxiety and can reduce nausea
  • For pain management, acetaminophen or NSAIDs are preferred over opioids, which can worsen nausea

Long-term Management

For long-term management, counseling to achieve marijuana cessation and tricyclic antidepressants, such as amitriptyline, are the mainstay of therapy, with the minimal effective dose being 75–100 mg at bedtime, starting at 25 mg and titrating the dose with increments each week to reach minimal effective dose 1. It's also important to note that combining evidence-based psychosocial interventions and pharmacology may be necessary for successful long-term management of CHS 1.

Important Considerations

  • Opioids should be avoided due to worsening of nausea and high risk of addiction 1
  • Patients should understand that symptoms will recur if cannabis use resumes, as CHS results from chronic cannabinoid stimulation of CB1 receptors, leading to paradoxical effects on the digestive system and thermoregulatory centers
  • Co-management with a psychologist or psychiatrist may be helpful for patients who have a lack of response to standard therapies or extensive psychiatric comorbidity 1

From the Research

Treatment Options for Cannabinoid Hyperemesis Syndrome (CHS)

  • The treatment for CHS is multifaceted and may involve a combination of pharmacological and non-pharmacological therapies 2, 3, 4, 5, 6.
  • Cessation of cannabis use is widely accepted as the most effective cure for CHS 3, 5.
  • Pharmacological treatments that have shown promise in managing CHS symptoms include:
    • Benzodiazepines, which may help decrease the activation of Cannabinoid Type 1 Receptor (CB1) in the frontal cortex and have a sedative and hypnotic effect 2, 3.
    • Antipsychotics, such as haloperidol, which may be effective in treating CHS symptoms 3, 5.
    • Droperidol, a dopamine antagonist, which has been shown to reduce the length of hospital stay and the total number of antiemetic dosages administered in CHS patients 6.
    • Topical capsaicin, which may help alleviate CHS symptoms 3, 4.
  • Non-pharmacological therapies that may be beneficial in managing CHS symptoms include:
    • Hot showers or baths, which can provide relief from symptoms 3, 4.
    • Hydrothermotherapy, which may help alleviate CHS symptoms 3.

Considerations for Treatment

  • It is essential to consider the patient's history of cannabis use and the effect of hydrothermotherapy on CHS symptoms when diagnosing and treating CHS 3, 4.
  • Directed questions about cannabis use and the effect of hydrothermotherapy on CHS symptoms can help confirm the diagnosis and enable appropriate pharmacotherapy and referral to addiction treatment 3.
  • Emergency medicine pharmacists should be able to recognize the common presentation of CHS and assist with treatment of these patients in the emergency department 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case Series.

The Israel Medical Association journal : IMAJ, 2019

Research

Managing cannabinoid hyperemesis syndrome in adult patients in the emergency department.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.